Project Grant R01CA276771
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$357K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Wauwatosa, WI 53226, USA
Similar Awards
This $657,776 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a highly tumor-selective pan-RAS inactivator for targeting oncogenic RAS-driven cancers. The award will fund comprehensive characterization and evaluation of this novel agent's anti-tumor activity using a wide range of tumor models. The objective is to develop a tumor-selective, safe, and highly potent pan-RAS inactivator that has high clinical utility for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $269,280 to Cold Spring Harbor Laboratory to conduct research on a novel targeted approach for treating K-RAS(G12C) mutation-driven cancers. The research aims to develop prodrug molecules that can selectively degrade the K-RAS(G12C) oncogenic protein while simultaneously releasing cytotoxic natural products to target multiple cancer pathways. Key objectives include determining the...
The National Cancer Institute (NCI) awarded a $162,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund research focused on "Targeting the HER Family in KRAS Mutant Colorectal Cancer." The research aims to determine the efficacy of co-targeting HER3 and KRAS in KRAS mutant colorectal cancer cell lines and patient-derived xenografts, as well as delineate the adaptive...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,827 to New York University School of Medicine to conduct research aimed at enhancing KRAS inhibitor therapy for cancer. The key objectives are to: 1) Evaluate four serine/threonine kinase family members as synthetic lethal targets and clarify the mechanistic basis for this synthetic lethality, and 2) Use CRISPR/Cas9 "mini-libraries" to define the synthetic...
This federal Project Grant award of $589,838.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Johns Hopkins University. The grant supports research to optimize an active mutant KRAS peptide vaccine for the treatment of colorectal cancer (CRC), which is the second leading cause of cancer-related mortality in the U.S. The research aims to develop improved methods for cancer treatment and increase cure rates for CRC patients....
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $636,046 to the Weill Medical College of Cornell University to conduct research aimed at defining the oncogenic potential and therapeutic dependencies of PDAC-associated KRAS variants. The key products and services to be delivered under this 5-year award, which began on November 25, 2024, include: Deciphering how cell lineage impacts the neoplastic transformation and molecular...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $433,256 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding supports research to identify novel targets and develop lead compounds to overcome resistance to KRAS inhibitors for lung, colon, and other cancers. The project leverages fragment-based chemoproteomics approaches to probe biological target...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) is providing $111,502.00 to The Ohio State University to support research on the biochemical properties and implications of NRAS mutant-specific BRAF interactions in melanoma. The goal is to elucidate the structural determinants and signaling mechanisms that drive the selectivity of specific NRAS mutations in melanoma development, which could help identify novel therapeutic approaches....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at overcoming rapid resistance to targeted therapies in colorectal cancer. The key products and services to be delivered under this 2-year award include: Evaluating how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer through analysis of...
The National Cancer Institute (NCI) awarded a $439,367 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center (UNMC) Division. The grant, titled "Assessment of Strategies for Targeting Transcriptional Co-Activators in Colorectal Cancer," aims to investigate the role of PGC-1 family proteins, specifically PGC-1B, in promoting the survival of colorectal...